For the second time this year, the U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) canceled a scheduled meeting due to a federal judge’s stay that keeps the panel from meeting with its current membership. Typically, ACIP meets three times a year – in February, June and October. The 2026 June meeting was slated for June 23-25. Whether the adcom meets in October will be up to the courts and how far Health and Human Services Secretary Robert Kennedy digs in his heels to maintain a hand-picked committee tilted toward his view of vaccines.

When it comes to vaccines and preparedness, platform delivery technologies can be both a boon and a barrier. On the one hand, an existing platform can speed development of a vaccine targeting an unexpected viral scare such as the recent Bundibugyo Ebola and Andes hantavirus outbreaks. On the other hand, the intellectual property (IP) protecting that platform adds to the economic hurdles facing smaller vaccine developers, Douglas Bucklin, a life sciences patent attorney with Volpe Koenig, told BioWorld.

The outbreak of hantavirus infection first reported on the MV Hondius cruise ship on May 2 is all but over, with most isolating passengers, crew members and other contacts leaving quarantine over the past week, as the 42-day incubation period drew to an end.

Molecular subtyping of disease is typically associated with cancer. Now, researchers at the University of Cambridge are applying it to infections.

Researchers at the Wyss Institute of Harvard University have used a mix of machine learning and classical screening techniques to identify small molecules that were effective against Neisseria gonorrhoeae in vagina-on-a-chip and mouse models of infection. Their findings were published in the June 17, 2026, issue of Science Translational Medicine.

Four years after the U.S. FDA issued a complete response letter for Spero Therapeutics Inc.’s oral antibiotic, tebipenem pivoxil hydrobromide, to treat complicated urinary tract infections (cUTI), including pyelonephritis, the agency approved the drug based on phase III data showing noninferiority to intravenous imipenem-cilastatin.

The U.S. FDA’s Vaccines and Related Biological Products Advisory Committee voted unanimously in favor of Moderna Inc.’s trivalent mRNA flu vaccine, mRNA-1010, which the company wants to brand as Mflusiva. On the question of whether the benefits of the product outweigh the risks in people ages 50 to 64, balloting was 9-0, and on whether the same is true in those 65 and older, the tally was again 9-0.

Three years on from the rebuff of a U.S. FDA complete response letter, F2G Ltd. now has the data needed to resubmit the NDA for the first novel antifungal drug in more than two decades. Along with partner Shionogi & Co. Ltd., F2G has released positive phase III results for orally administered olorofim, showing noninferiority against I.V.-administered Ambisome (amphotericin B, Gilead Sciences Inc.) in patients with refractory aspergillosis infections, or who were unsuitable for mainstay azole therapy.

On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers at Washington University School of Medicine in St. Louis have reported that the vaccine conferred broader and more durable protection than a standard flu shot.

Moderna Inc. will soon find out if the tumult-ridden U.S. FDA’s switcheroo in mid-February will stick regarding mRNA-1010, a prospective new seasonal influenza vaccine. The Vaccines and Related Biological Products Advisory Committee on June 17 takes up the matter of the shot, which trails a curious history.